ARQT - Arcutis drug helps seborrheic dermatitis patients get clearer skin meets main goal of study

Arcutis Biotherapeutics (NASDAQ:ARQT) said its medicine roflumilast foam helped reduce severity of a skin disease called seborrheic dermatitis, meeting the main goal of a late-stage study. Seborrheic dermatitis is a skin condition which mainly affects the scalp, causing scaly patches, redness and dandruff. The phase 3 trial, dubbed STRATUM, evaluated topical roflumilast foam versus vehicle to treat adolescents and adults with moderate to severe seborrheic dermatitis. The company said the trial met the main goal with 80.1% of people treated with roflumilast foam achieving Investigator Global Assessment (IGA) compared to 59.2% of patients treated with vehicle. IGA is a measure of measure of disease severity. IGA success was defined as an IGA score of clear or almost clear skin plus a ?2 grade improvement from the time treatment began, the company noted. Arcutis (ARQT) added that Improvement with roflumilast foam was seen early by week 2, compared to patients receiving vehicle. In addition, more than 50% of patients

For further details see:

Arcutis drug helps seborrheic dermatitis patients get clearer skin, meets main goal of study